

Global Severe Eosinophilic Asthma Treatment Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GE3A6484DE08EN.html>

Date: June 2026

Pages: 138

Price: US\$ 4,480.00 (Single User License)

ID: GE3A6484DE08EN

Abstracts

The global Severe Eosinophilic Asthma Treatment market size is expected to reach \$ 17519 million by 2032, rising at a market growth of 10.5% CAGR during the forecast period (2026-2032).

The gross profit margin of major companies in the industry is between 58% ? 78%.

Severe Eosinophilic Asthma Treatment refers to therapeutic regimens used for patients with severe asthma characterized by elevated eosinophil-driven inflammation. The category includes biologics, targeted monoclonal antibodies, and advanced maintenance therapies aimed at reducing exacerbations, improving lung function, and lowering corticosteroid dependence. It has become an important segment within specialty respiratory care and precision immunology treatment.

The industrial chain of Severe Eosinophilic Asthma Treatment includes upstream biologic raw materials, cell culture media, active pharmaceutical ingredients, vials, syringes, and cold-chain materials. Midstream covers drug development, biomanufacturing, filling, packaging, and regulatory control. Downstream applications mainly include hospitals, specialty clinics, respiratory care centers, pharmacies, and long-term chronic disease management programs.

The market for severe eosinophilic asthma treatments is expanding due to rising prevalence of respiratory diseases and unmet medical needs. Biologics targeting eosinophilic inflammation have become mainstream for uncontrolled severe asthma. Increasing diagnosis rates, improved access to specialty drugs, and favorable reimbursement policies support growth. Companies focus on innovative targeted therapies and long-term safety to strengthen clinical competitiveness.

This report studies the global Severe Eosinophilic Asthma Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Severe Eosinophilic Asthma Treatment, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Severe Eosinophilic Asthma Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Severe Eosinophilic Asthma Treatment total market, 2021-2032, (USD Million)

Global Severe Eosinophilic Asthma Treatment total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Severe Eosinophilic Asthma Treatment total market, key domestic companies, and share, (USD Million)

Global Severe Eosinophilic Asthma Treatment revenue by player, revenue and market share 2021-2026, (USD Million)

Global Severe Eosinophilic Asthma Treatment total market by Type, CAGR, 2021-2032, (USD Million)

Global Severe Eosinophilic Asthma Treatment total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Severe Eosinophilic Asthma Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, GSK (GlaxoSmithKline), Sanofi, Regeneron Pharmaceuticals, Novartis, Roche (Genentech), Teva Pharmaceutical, Amgen, TEPPON (Kyowa Kirin), Jiangsu Hengrui Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Severe Eosinophilic Asthma Treatment market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$

Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Severe Eosinophilic Asthma Treatment Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Severe Eosinophilic Asthma Treatment Market, Segmentation by Type:

Intravenous Infusion

Subcutaneous Injection

Global Severe Eosinophilic Asthma Treatment Market, Segmentation by Administration Route:

Inhalation Therapy

Subcutaneous Injection Therapy

Intravenous Infusion Therapy

Global Severe Eosinophilic Asthma Treatment Market, Segmentation by Treatment Stage:

Induction Remission Therapy

Maintenance Control Therapy

Exacerbation Rescue Therapy

Global Severe Eosinophilic Asthma Treatment Market, Segmentation by Application:

Adult Severe Eosinophilic Asthma

Adolescent Severe Eosinophilic Asthma

Elderly Comorbid Asthma

Companies Profiled:

AstraZeneca

GSK (GlaxoSmithKline)

Sanofi

Regeneron Pharmaceuticals

Novartis

Roche (Genentech)

Teva Pharmaceutical

Amgen

TEPPON (Kyowa Kirin)

Jiangsu Hengrui Pharmaceuticals

CSPC Pharmaceutical Group

3SBio (Sunshine Guojian)

Akeso

InnoCare Pharma

Innovent Biologics

Mabwell Bioscience

Key Questions Answered

1. How big is the global Severe Eosinophilic Asthma Treatment market?
2. What is the demand of the global Severe Eosinophilic Asthma Treatment market?
3. What is the year over year growth of the global Severe Eosinophilic Asthma Treatment market?
4. What is the total value of the global Severe Eosinophilic Asthma Treatment market?
5. Who are the Major Players in the global Severe Eosinophilic Asthma Treatment market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Severe Eosinophilic Asthma Treatment Introduction
- 1.2 World Severe Eosinophilic Asthma Treatment Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Severe Eosinophilic Asthma Treatment Total Market by Region (by Headquarter Location)
 - 1.3.1 World Severe Eosinophilic Asthma Treatment Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.3 China Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.4 Europe Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.5 Japan Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
 - 1.3.8 India Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Severe Eosinophilic Asthma Treatment Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)
- 2.2 World Severe Eosinophilic Asthma Treatment Consumption Value by Region
 - 2.2.1 World Severe Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026)
 - 2.2.2 World Severe Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Severe Eosinophilic Asthma Treatment Consumption Value

(2021-2032)

2.4 China Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)

2.5 Europe Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)

2.6 Japan Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)

2.7 South Korea Severe Eosinophilic Asthma Treatment Consumption Value
(2021-2032)

2.8 ASEAN Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)

2.9 India Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032)

3 WORLD SEVERE EOSINOPHILIC ASTHMA TREATMENT COMPANIES COMPETITIVE ANALYSIS

3.1 World Severe Eosinophilic Asthma Treatment Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Severe Eosinophilic Asthma Treatment Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Severe Eosinophilic Asthma Treatment in
2025

3.2.3 Global Concentration Ratios (CR8) for Severe Eosinophilic Asthma Treatment in
2025

3.3 Severe Eosinophilic Asthma Treatment Company Evaluation Quadrant

3.4 Severe Eosinophilic Asthma Treatment Market: Overall Company Footprint Analysis

3.4.1 Severe Eosinophilic Asthma Treatment Market: Region Footprint

3.4.2 Severe Eosinophilic Asthma Treatment Market: Company Product Type Footprint

3.4.3 Severe Eosinophilic Asthma Treatment Market: Company Product Application
Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Severe Eosinophilic Asthma Treatment Revenue
Comparison (by Headquarter Location)

4.1.1 United States VS China: Severe Eosinophilic Asthma Treatment Revenue
Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: Severe Eosinophilic Asthma Treatment Revenue Market

Share Comparison (2021 & 2025 & 2032)

4.2 United States Based Companies VS China Based Companies: Severe Eosinophilic Asthma Treatment Consumption Value Comparison

4.2.1 United States VS China: Severe Eosinophilic Asthma Treatment Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Severe Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Severe Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026

4.3.1 United States Based Severe Eosinophilic Asthma Treatment Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Severe Eosinophilic Asthma Treatment Revenue, (2021-2026)

4.4 China Based Companies Severe Eosinophilic Asthma Treatment Revenue and Market Share, 2021-2026

4.4.1 China Based Severe Eosinophilic Asthma Treatment Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Severe Eosinophilic Asthma Treatment Revenue, (2021-2026)

4.5 Rest of World Based Severe Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Severe Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Severe Eosinophilic Asthma Treatment Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Severe Eosinophilic Asthma Treatment Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Intravenous Infusion

5.2.2 Subcutaneous Injection

5.3 Market Segment by Type

5.3.1 World Severe Eosinophilic Asthma Treatment Market Size by Type (2021-2026)

5.3.2 World Severe Eosinophilic Asthma Treatment Market Size by Type (2027-2032)

5.3.3 World Severe Eosinophilic Asthma Treatment Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY ADMINISTRATION ROUTE

- 6.1 World Severe Eosinophilic Asthma Treatment Market Size Overview by Administration Route: 2021 VS 2025 VS 2032
- 6.2 Segment Introduction by Administration Route
 - 6.2.1 Inhalation Therapy
 - 6.2.2 Subcutaneous Injection Therapy
 - 6.2.3 Intravenous Infusion Therapy
- 6.3 Market Segment by Administration Route
 - 6.3.1 World Severe Eosinophilic Asthma Treatment Market Size by Administration Route (2021-2026)
 - 6.3.2 World Severe Eosinophilic Asthma Treatment Market Size by Administration Route (2027-2032)
 - 6.3.3 World Severe Eosinophilic Asthma Treatment Market Size Market Share by Administration Route (2027-2032)

7 MARKET ANALYSIS BY TREATMENT STAGE

- 7.1 World Severe Eosinophilic Asthma Treatment Market Size Overview by Treatment Stage: 2021 VS 2025 VS 2032
- 7.2 Segment Introduction by Treatment Stage
 - 7.2.1 Induction Remission Therapy
 - 7.2.2 Maintenance Control Therapy
 - 7.2.3 Exacerbation Rescue Therapy
- 7.3 Market Segment by Treatment Stage
 - 7.3.1 World Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage (2021-2026)
 - 7.3.2 World Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage (2027-2032)
 - 7.3.3 World Severe Eosinophilic Asthma Treatment Market Size Market Share by Treatment Stage (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

- 8.1 World Severe Eosinophilic Asthma Treatment Market Size Overview by Application: 2021 VS 2025 VS 2032
- 8.2 Segment Introduction by Application
 - 8.2.1 Adult Severe Eosinophilic Asthma
 - 8.2.2 Adolescent Severe Eosinophilic Asthma

8.2.3 Elderly Comorbid Asthma

8.3 Market Segment by Application

8.3.1 World Severe Eosinophilic Asthma Treatment Market Size by Application (2021-2026)

8.3.2 World Severe Eosinophilic Asthma Treatment Market Size by Application (2027-2032)

8.3.3 World Severe Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 AstraZeneca

9.1.1 AstraZeneca Details

9.1.2 AstraZeneca Major Business

9.1.3 AstraZeneca Severe Eosinophilic Asthma Treatment Product and Services

9.1.4 AstraZeneca Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 AstraZeneca Recent Developments/Updates

9.1.6 AstraZeneca Competitive Strengths & Weaknesses

9.2 GSK (GlaxoSmithKline)

9.2.1 GSK (GlaxoSmithKline) Details

9.2.2 GSK (GlaxoSmithKline) Major Business

9.2.3 GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Product and Services

9.2.4 GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.2.5 GSK (GlaxoSmithKline) Recent Developments/Updates

9.2.6 GSK (GlaxoSmithKline) Competitive Strengths & Weaknesses

9.3 Sanofi

9.3.1 Sanofi Details

9.3.2 Sanofi Major Business

9.3.3 Sanofi Severe Eosinophilic Asthma Treatment Product and Services

9.3.4 Sanofi Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.3.5 Sanofi Recent Developments/Updates

9.3.6 Sanofi Competitive Strengths & Weaknesses

9.4 Regeneron Pharmaceuticals

9.4.1 Regeneron Pharmaceuticals Details

9.4.2 Regeneron Pharmaceuticals Major Business

- 9.4.3 Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Services
- 9.4.4 Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
- 9.4.5 Regeneron Pharmaceuticals Recent Developments/Updates
- 9.4.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
- 9.5 Novartis
 - 9.5.1 Novartis Details
 - 9.5.2 Novartis Major Business
 - 9.5.3 Novartis Severe Eosinophilic Asthma Treatment Product and Services
 - 9.5.4 Novartis Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.5.5 Novartis Recent Developments/Updates
 - 9.5.6 Novartis Competitive Strengths & Weaknesses
- 9.6 Roche (Genentech)
 - 9.6.1 Roche (Genentech) Details
 - 9.6.2 Roche (Genentech) Major Business
 - 9.6.3 Roche (Genentech) Severe Eosinophilic Asthma Treatment Product and Services
 - 9.6.4 Roche (Genentech) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.6.5 Roche (Genentech) Recent Developments/Updates
 - 9.6.6 Roche (Genentech) Competitive Strengths & Weaknesses
- 9.7 Teva Pharmaceutical
 - 9.7.1 Teva Pharmaceutical Details
 - 9.7.2 Teva Pharmaceutical Major Business
 - 9.7.3 Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Product and Services
 - 9.7.4 Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.7.5 Teva Pharmaceutical Recent Developments/Updates
 - 9.7.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
- 9.8 Amgen
 - 9.8.1 Amgen Details
 - 9.8.2 Amgen Major Business
 - 9.8.3 Amgen Severe Eosinophilic Asthma Treatment Product and Services
 - 9.8.4 Amgen Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.8.5 Amgen Recent Developments/Updates
 - 9.8.6 Amgen Competitive Strengths & Weaknesses

9.9 TEPPON (Kyowa Kirin)

9.9.1 TEPPON (Kyowa Kirin) Details

9.9.2 TEPPON (Kyowa Kirin) Major Business

9.9.3 TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Product and Services

9.9.4 TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.9.5 TEPPON (Kyowa Kirin) Recent Developments/Updates

9.9.6 TEPPON (Kyowa Kirin) Competitive Strengths & Weaknesses

9.10 Jiangsu Hengrui Pharmaceuticals

9.10.1 Jiangsu Hengrui Pharmaceuticals Details

9.10.2 Jiangsu Hengrui Pharmaceuticals Major Business

9.10.3 Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Services

9.10.4 Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

9.10.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses

9.11 CSPC Pharmaceutical Group

9.11.1 CSPC Pharmaceutical Group Details

9.11.2 CSPC Pharmaceutical Group Major Business

9.11.3 CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Product and Services

9.11.4 CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.11.5 CSPC Pharmaceutical Group Recent Developments/Updates

9.11.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses

9.12 3SBio (Sunshine Guojian)

9.12.1 3SBio (Sunshine Guojian) Details

9.12.2 3SBio (Sunshine Guojian) Major Business

9.12.3 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Product and Services

9.12.4 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)

9.12.5 3SBio (Sunshine Guojian) Recent Developments/Updates

9.12.6 3SBio (Sunshine Guojian) Competitive Strengths & Weaknesses

9.13 Akeso

9.13.1 Akeso Details

9.13.2 Akeso Major Business

- 9.13.3 Akeso Severe Eosinophilic Asthma Treatment Product and Services
- 9.13.4 Akeso Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
- 9.13.5 Akeso Recent Developments/Updates
- 9.13.6 Akeso Competitive Strengths & Weaknesses
- 9.14 InnoCare Pharma
 - 9.14.1 InnoCare Pharma Details
 - 9.14.2 InnoCare Pharma Major Business
 - 9.14.3 InnoCare Pharma Severe Eosinophilic Asthma Treatment Product and Services
 - 9.14.4 InnoCare Pharma Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.14.5 InnoCare Pharma Recent Developments/Updates
 - 9.14.6 InnoCare Pharma Competitive Strengths & Weaknesses
- 9.15 Innovent Biologics
 - 9.15.1 Innovent Biologics Details
 - 9.15.2 Innovent Biologics Major Business
 - 9.15.3 Innovent Biologics Severe Eosinophilic Asthma Treatment Product and Services
 - 9.15.4 Innovent Biologics Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.15.5 Innovent Biologics Recent Developments/Updates
 - 9.15.6 Innovent Biologics Competitive Strengths & Weaknesses
- 9.16 Mabwell Bioscience
 - 9.16.1 Mabwell Bioscience Details
 - 9.16.2 Mabwell Bioscience Major Business
 - 9.16.3 Mabwell Bioscience Severe Eosinophilic Asthma Treatment Product and Services
 - 9.16.4 Mabwell Bioscience Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
 - 9.16.5 Mabwell Bioscience Recent Developments/Updates
 - 9.16.6 Mabwell Bioscience Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

- 10.1 Severe Eosinophilic Asthma Treatment Industry Chain
- 10.2 Severe Eosinophilic Asthma Treatment Upstream Analysis
- 10.3 Severe Eosinophilic Asthma Treatment Midstream Analysis
- 10.4 Severe Eosinophilic Asthma Treatment Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Severe Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World Severe Eosinophilic Asthma Treatment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World Severe Eosinophilic Asthma Treatment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World Severe Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World Severe Eosinophilic Asthma Treatment Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Severe Eosinophilic Asthma Treatment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World Severe Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World Severe Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World Severe Eosinophilic Asthma Treatment Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key Severe Eosinophilic Asthma Treatment Players in 2025

Table 12. World Severe Eosinophilic Asthma Treatment Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global Severe Eosinophilic Asthma Treatment Company Evaluation Quadrant

Table 14. Head Office of Key Severe Eosinophilic Asthma Treatment Players

Table 15. Severe Eosinophilic Asthma Treatment Market: Company Product Type Footprint

Table 16. Severe Eosinophilic Asthma Treatment Market: Company Product Application Footprint

Table 17. Severe Eosinophilic Asthma Treatment Mergers & Acquisitions Activity

Table 18. United States VS China Severe Eosinophilic Asthma Treatment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China Severe Eosinophilic Asthma Treatment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based Severe Eosinophilic Asthma Treatment Companies,

Headquarters (States, Country)

Table 21. United States Based Companies Severe Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Severe Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)

Table 23. China Based Severe Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)

Table 24. China Based Companies Severe Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Severe Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)

Table 26. Rest of World Based Severe Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Severe Eosinophilic Asthma Treatment Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Severe Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)

Table 29. World Severe Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Severe Eosinophilic Asthma Treatment Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Severe Eosinophilic Asthma Treatment Market Size by Type (2027-2032) & (USD Million)

Table 32. World Severe Eosinophilic Asthma Treatment Market Size by Administration Route, (USD Million), 2021 & 2025 & 2032

Table 33. World Severe Eosinophilic Asthma Treatment Market Size Value by Administration Route (2021-2026) & (USD Million)

Table 34. World Severe Eosinophilic Asthma Treatment Market Size by Administration Route (2027-2032) & (USD Million)

Table 35. World Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage, (USD Million), 2021 & 2025 & 2032

Table 36. World Severe Eosinophilic Asthma Treatment Market Size Value by Treatment Stage (2021-2026) & (USD Million)

Table 37. World Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage (2027-2032) & (USD Million)

Table 38. World Severe Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World Severe Eosinophilic Asthma Treatment Market Size by Application (2021-2026) & (USD Million)

Table 40. World Severe Eosinophilic Asthma Treatment Market Size by Application (2027-2032) & (USD Million)

Table 41. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 42. AstraZeneca Major Business

Table 43. AstraZeneca Severe Eosinophilic Asthma Treatment Product and Services

Table 44. AstraZeneca Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. AstraZeneca Recent Developments/Updates

Table 46. AstraZeneca Competitive Strengths & Weaknesses

Table 47. GSK (GlaxoSmithKline) Basic Information, Manufacturing Base and Competitors

Table 48. GSK (GlaxoSmithKline) Major Business

Table 49. GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Product and Services

Table 50. GSK (GlaxoSmithKline) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 51. GSK (GlaxoSmithKline) Recent Developments/Updates

Table 52. GSK (GlaxoSmithKline) Competitive Strengths & Weaknesses

Table 53. Sanofi Basic Information, Manufacturing Base and Competitors

Table 54. Sanofi Major Business

Table 55. Sanofi Severe Eosinophilic Asthma Treatment Product and Services

Table 56. Sanofi Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 57. Sanofi Recent Developments/Updates

Table 58. Sanofi Competitive Strengths & Weaknesses

Table 59. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 60. Regeneron Pharmaceuticals Major Business

Table 61. Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Services

Table 62. Regeneron Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 63. Regeneron Pharmaceuticals Recent Developments/Updates

Table 64. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses

Table 65. Novartis Basic Information, Manufacturing Base and Competitors

Table 66. Novartis Major Business

Table 67. Novartis Severe Eosinophilic Asthma Treatment Product and Services

Table 68. Novartis Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 69. Novartis Recent Developments/Updates
Table 70. Novartis Competitive Strengths & Weaknesses
Table 71. Roche (Genentech) Basic Information, Manufacturing Base and Competitors
Table 72. Roche (Genentech) Major Business
Table 73. Roche (Genentech) Severe Eosinophilic Asthma Treatment Product and Services
Table 74. Roche (Genentech) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Roche (Genentech) Recent Developments/Updates
Table 76. Roche (Genentech) Competitive Strengths & Weaknesses
Table 77. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 78. Teva Pharmaceutical Major Business
Table 79. Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Product and Services
Table 80. Teva Pharmaceutical Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Teva Pharmaceutical Recent Developments/Updates
Table 82. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 83. Amgen Basic Information, Manufacturing Base and Competitors
Table 84. Amgen Major Business
Table 85. Amgen Severe Eosinophilic Asthma Treatment Product and Services
Table 86. Amgen Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Amgen Recent Developments/Updates
Table 88. Amgen Competitive Strengths & Weaknesses
Table 89. TEPPON (Kyowa Kirin) Basic Information, Manufacturing Base and Competitors
Table 90. TEPPON (Kyowa Kirin) Major Business
Table 91. TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Product and Services
Table 92. TEPPON (Kyowa Kirin) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. TEPPON (Kyowa Kirin) Recent Developments/Updates
Table 94. TEPPON (Kyowa Kirin) Competitive Strengths & Weaknesses
Table 95. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 96. Jiangsu Hengrui Pharmaceuticals Major Business
Table 97. Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Product and Services

Table 98. Jiangsu Hengrui Pharmaceuticals Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

Table 100. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses

Table 101. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors

Table 102. CSPC Pharmaceutical Group Major Business

Table 103. CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Product and Services

Table 104. CSPC Pharmaceutical Group Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 105. CSPC Pharmaceutical Group Recent Developments/Updates

Table 106. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses

Table 107. 3SBio (Sunshine Guojian) Basic Information, Manufacturing Base and Competitors

Table 108. 3SBio (Sunshine Guojian) Major Business

Table 109. 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Product and Services

Table 110. 3SBio (Sunshine Guojian) Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 111. 3SBio (Sunshine Guojian) Recent Developments/Updates

Table 112. 3SBio (Sunshine Guojian) Competitive Strengths & Weaknesses

Table 113. Akeso Basic Information, Manufacturing Base and Competitors

Table 114. Akeso Major Business

Table 115. Akeso Severe Eosinophilic Asthma Treatment Product and Services

Table 116. Akeso Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 117. Akeso Recent Developments/Updates

Table 118. Akeso Competitive Strengths & Weaknesses

Table 119. InnoCare Pharma Basic Information, Manufacturing Base and Competitors

Table 120. InnoCare Pharma Major Business

Table 121. InnoCare Pharma Severe Eosinophilic Asthma Treatment Product and Services

Table 122. InnoCare Pharma Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 123. InnoCare Pharma Recent Developments/Updates

Table 124. InnoCare Pharma Competitive Strengths & Weaknesses

Table 125. Innovent Biologics Basic Information, Manufacturing Base and Competitors

Table 126. Innovent Biologics Major Business

Table 127. Innovent Biologics Severe Eosinophilic Asthma Treatment Product and Services

Table 128. Innovent Biologics Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 129. Innovent Biologics Recent Developments/Updates

Table 130. Innovent Biologics Competitive Strengths & Weaknesses

Table 131. Mabwell Bioscience Basic Information, Manufacturing Base and Competitors

Table 132. Mabwell Bioscience Major Business

Table 133. Mabwell Bioscience Severe Eosinophilic Asthma Treatment Product and Services

Table 134. Mabwell Bioscience Severe Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 135. Mabwell Bioscience Recent Developments/Updates

Table 136. Mabwell Bioscience Competitive Strengths & Weaknesses

Table 137. Global Key Players of Severe Eosinophilic Asthma Treatment Upstream (Raw Materials)

Table 138. Global Severe Eosinophilic Asthma Treatment Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Severe Eosinophilic Asthma Treatment Picture

Figure 2. World Severe Eosinophilic Asthma Treatment Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Severe Eosinophilic Asthma Treatment Total Revenue (2021-2032) & (USD Million)

Figure 4. World Severe Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World Severe Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company Severe Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)

Figure 13. Severe Eosinophilic Asthma Treatment Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 16. World Severe Eosinophilic Asthma Treatment Consumption Value Market Share by Region (2021-2032)

Figure 17. United States Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 18. China Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 23. India Severe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Severe Eosinophilic Asthma Treatment by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Severe Eosinophilic Asthma Treatment Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Severe Eosinophilic Asthma Treatment Markets in 2025

Figure 27. United States VS China: Severe Eosinophilic Asthma Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Severe Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Severe Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Type in 2025

Figure 31. Intravenous Infusion

Figure 32. Subcutaneous Injection

Figure 33. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Type (2021-2032)

Figure 34. World Severe Eosinophilic Asthma Treatment Market Size by Administration Route, (USD Million), 2021 & 2025 & 2032

Figure 35. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Administration Route in 2025

Figure 36. Inhalation Therapy

Figure 37. Subcutaneous Injection Therapy

Figure 38. Intravenous Infusion Therapy

Figure 39. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Administration Route (2021-2032)

Figure 40. World Severe Eosinophilic Asthma Treatment Market Size by Treatment Stage, (USD Million), 2021 & 2025 & 2032

Figure 41. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Treatment Stage in 2025

Figure 42. Induction Remission Therapy

Figure 43. Maintenance Control Therapy

Figure 44. Exacerbation Rescue Therapy

Figure 45. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Treatment Stage (2021-2032)

Figure 46. World Severe Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 47. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Application in 2025

Figure 48. Adult Severe Eosinophilic Asthma

Figure 49. Adolescent Severe Eosinophilic Asthma

Figure 50. Elderly Comorbid Asthma

Figure 51. World Severe Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)

Figure 52. Severe Eosinophilic Asthma Treatment Industrial Chain

Figure 53. Methodology

Figure 54. Research Process and Data Source

I would like to order

Product name: Global Severe Eosinophilic Asthma Treatment Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GE3A6484DE08EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE3A6484DE08EN.html>